Medications

Trial results of new drug for generalized myasthenia gravis

Argenx, a Belgium pharmaceutical company, recently announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living ...

Diseases, Conditions, Syndromes

NY airports, hospitals under pressure as virus cases mount

The Federal Aviation Administration briefly suspended flights to New York City-area airports on Saturday because of coronavirus-related staffing issues as the number of confirmed cases in New York state soared above 10,000.

Neuroscience

Management of MS in pregnancy reviewed in U.K. guideline

(HealthDay)—It is important to discuss family planning and pregnancy proactively in women of childbearing age who have multiple sclerosis (MS), according to a review published online Jan. 5 in Practical Neurology.

Diabetes

FDA expands approval of closed-looped insulin delivery system

(HealthDay)—Approval of the MiniMed 670G hybrid closed looped system for diabetes management has been expanded to include individuals aged 7 to 13 years with type 1 diabetes, according to a report published by the U.S. ...

page 4 from 9